← All trials
NCT05778071
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- Jun 30, 2025
- First posted
- Mar 21, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 165
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Amolyt PharmaLead sponsor
- Amolyt PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.